荃信生物（2509.HK）

About

Quanxin Biopharma (荃信生物, 2509.HK) was founded in 2015 and is a late clinical-stage biopharmaceutical company focused on biological therapies for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale in-house manufacturing capability. Quanxin Biopharma upholds the philosophy of "innovating for the greatest number of patients" and strives to address drug accessibility and affordability in its fields of focus. 勤智资本 (Qinzhi Capital) participated in the company's Series B, Series B++ and Series C financings in May 2019, April 2021 and February 2022 respectively.